Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleMetabolism, Transport, and Pharmacogenomics

Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors

Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics November 4, 2016, jpet.116.237594; DOI: https://doi.org/10.1124/jpet.116.237594
Julie-Anne Tanner
1 University of Toronto;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhagwat Prasad
2 University of Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrina G. Claw
2 University of Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Stapleton
2 University of Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amarjit Chaudhry
3 St Jude Children's Research Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin G. Schuetz
3 St Jude Children's Research Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth E. Thummel
2 University of Washington;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel F. Tyndale
4 University of Toronto; Centre for Addiction and Mental Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Cytochrome P450 2A6 (CYP2A6) metabolizes several clinically relevant substrates, including nicotine, the primary psychoactive component in cigarette smoke. Smokers vary widely in their rate of inactivation and clearance of nicotine, altering numerous smoking phenotypes. We aimed to characterize independent and shared impact of genetic and non-genetic sources of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank (n=360). We quantified levels of CYP2A6, cytochrome P450 oxidoreductase (POR), and aldo-keto reductase 1D1 (AKR1D1) mRNA, and CYP2A6 and POR protein. CYP2A6 enzyme activity was determined through measurement of cotinine formation from nicotine and 7-hydroxycoumarin formation from coumarin. Donor DNA was genotyped for CYP2A6, POR, and AKR1D1 genetic variants. CYP2A6 phenotype measures were moderately to strongly correlated (r values ranging from 0.47-0.88, P<0.001). Female donors exhibited higher CYP2A6 mRNA expression relative to males (P<0.05). Donor age was weakly correlated with CYP2A6 protein (r=0.12, P<0.05) and activity (r=0.20, P<0.001). CYP2A6 reduce-of-function genotypes, but not POR or AKR1D1 genotype, were associated with lower CYP2A6 protein (P<0.001) and activity (P<0.01). AKR1D1 mRNA was moderately correlated with CYP2A6 mRNA (r=0.57, P<0.001), protein (r=0.30, P<0.001), and activity (r=0.34, P<0.001). POR protein was moderately correlated with CYP2A6 activity (r=0.45, P<0.001). Through regression analyses, 17% (P<0.001), 37% (P<0.001), and 77% (P<0.001) of the variation in CYP2A6 mRNA, protein, and activity, respectively, was accounted for by genetic and non-genetic factors. Overall, several independent and shared sources of variation in CYP2A6 activity in vitro have been identified, which could translate to variable hepatic clearance of nicotine.

  • CYP2A
  • drug metabolism
  • genetic polymorphism
  • nicotine
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleMetabolism, Transport, and Pharmacogenomics

Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors

Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics November 4, 2016, jpet.116.237594; DOI: https://doi.org/10.1124/jpet.116.237594

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleMetabolism, Transport, and Pharmacogenomics

Predictors of variation in CYP2A6 mRNA, protein, and enzyme activity in a human liver bank: influence of genetic and non-genetic factors

Julie-Anne Tanner, Bhagwat Prasad, Katrina G. Claw, Patricia Stapleton, Amarjit Chaudhry, Erin G. Schuetz, Kenneth E. Thummel and Rachel F. Tyndale
Journal of Pharmacology and Experimental Therapeutics November 4, 2016, jpet.116.237594; DOI: https://doi.org/10.1124/jpet.116.237594
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • HDL Mimetic 4F Modulates Aβ Distribution in Brain and Plasma
  • AOX1 Inhibition by Gefitinib, Erlotinib, and Metabolites
  • Catalytic Activity of CYP2C9 Variants
Show more Metabolism, Transport, and Pharmacogenomics

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics